Switch theme
Sign up to access all valuation multiples
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Innoviva has a last 12-month revenue of $360M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Innoviva achieved revenue of $359M and an EBITDA of $85.5M.
Innoviva expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Innoviva valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $310M | $359M | XXX | XXX | XXX |
| Gross Profit | $318M | $268M | XXX | XXX | XXX |
| Gross Margin | 102% | 75% | XXX | XXX | XXX |
| EBITDA | $235M | $85.5M | XXX | XXX | XXX |
| EBITDA Margin | 76% | 24% | XXX | XXX | XXX |
| Net Profit | $214M | $180M | XXX | XXX | XXX |
| Net Margin | 69% | 50% | XXX | XXX | XXX |
| Net Debt | $249M | $253M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Innoviva's stock price is $18.
Innoviva has current market cap of $1.1B, and EV of $1.2B.
See Innoviva trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2B | $1.1B | XXX | XXX | XXX | XXX | $0.66 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Innoviva has market cap of $1.1B and EV of $1.2B.
Innoviva's trades at 3.2x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Innoviva's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Innoviva and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.2B | XXX | XXX | XXX |
| EV/Revenue | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | 13.7x | XXX | XXX | XXX |
| P/E | 48.2x | XXX | XXX | XXX |
| P/E/Growth | 0.3x | XXX | XXX | XXX |
| EV/FCF | 6.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpInnoviva's NTM/LTM revenue growth is 5%
Innoviva's revenue per employee for the last fiscal year averaged $2.8M, while opex per employee averaged $1.2M for the same period.
Over next 12 months, Innoviva's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Innoviva's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Innoviva and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -64% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 29% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $2.8M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 43% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Innoviva acquired XXX companies to date.
Last acquisition by Innoviva was XXXXXXXX, XXXXX XXXXX XXXXXX . Innoviva acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Innoviva founded? | Innoviva was founded in 1996. |
| Where is Innoviva headquartered? | Innoviva is headquartered in United States of America. |
| How many employees does Innoviva have? | As of today, Innoviva has 127 employees. |
| Who is the CEO of Innoviva? | Innoviva's CEO is Mr. Pavel Raifeld. |
| Is Innoviva publicy listed? | Yes, Innoviva is a public company listed on NAS. |
| What is the stock symbol of Innoviva? | Innoviva trades under INVA ticker. |
| When did Innoviva go public? | Innoviva went public in 2004. |
| Who are competitors of Innoviva? | Similar companies to Innoviva include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Innoviva? | Innoviva's current market cap is $1.1B |
| What is the current revenue of Innoviva? | Innoviva's last 12-month revenue is $360M. |
| What is the current EV/Revenue multiple of Innoviva? | Current revenue multiple of Innoviva is 3.2x. |
| What is the current revenue growth of Innoviva? | Innoviva revenue growth between 2023 and 2024 was 16%. |
| Is Innoviva profitable? | Yes, Innoviva is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
